Base de dados : MEDLINE
Pesquisa : D02.033.100.624.605 [Categoria DeCS]
Referências encontradas : 122 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 13 ir para página                         

  1 / 122 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
[PMID]:22364032
[Au] Autor:Montijo-Barrios E; Cadena F; Ramírez-Mayans JA; Gutiérrez-Castrellón P
[Ad] Endereço:Instituto Nacional de Pediatría, Secretaría de Salud.
[Ti] Título:[Clinical trial on the effect of buphenine, aminophenazone and diphenylpyraline hydrochloride in treating the common cold in children of 6 to 24 months of age].
[Ti] Título:Ensayo clínico sobre el efecto de la bufenina, aminofenazona y el clorhidrato de difenilpiralina en el tratamiento del resfriado común en niños de seis a 24 meses de edad..
[So] Source:Rev Invest Clin;63(4):335-43, 2011 Jul-Aug.
[Is] ISSN:0034-8376
[Cp] País de publicação:Mexico
[La] Idioma:spa
[Ab] Resumo:INTRODUCTION: Acute respiratory infections are the second leading cause of morbidity in children under 18 years. Several drugs have been used with variable efficacy and safety, trying to reduce the associated symptoms and improve quality of life. OBJECTIVE: To evaluate the efficacy and safety of buphenine, aminophenazone and diphenylpyraline hydrochloride when compared with placebo for the control of symptoms associated with common cold in children 6-24 months of age. MATERIAL AND METHODS: Randomized clinical trial, double blind, placebo controlled, in 100 children < 24 months of any gender, with symptoms associated to common cold. They received the drug under study vs. placebo for seven days. Both groups received acetaminophen. The change on common cold related symptoms were evaluated. Statistic analysis was made with STATA 11.0 for Mac. RESULTS: Fifty-three children were randomized to study drug and forty-seven to placebo. Age of children in each group was similar (12.2 +/- 5.8 months vs. 12.7 +/- 5.8 months, p NS). There were significant differences between groups in relation to rhinorrea and sneezing resolution, with better results in Flumil group and no adverse events observed. CONCLUSIONS: The results in this study indicates that Flumil is a safe and effective drug for control of symptoms present in the common cold in children aged 6-24 months.
[Mh] Termos MeSH primário: Aminopirina/uso terapêutico
Resfriado Comum/tratamento farmacológico
Nilidrina/uso terapêutico
Piperidinas/uso terapêutico
[Mh] Termos MeSH secundário: Acetaminofen/administração & dosagem
Acetaminofen/uso terapêutico
Aminopirina/administração & dosagem
Pré-Escolar
Método Duplo-Cego
Quimioterapia Combinada
Feminino
Seres Humanos
Lactente
Masculino
Mucosa Nasal/secreção
Nilidrina/administração & dosagem
Piperidinas/administração & dosagem
Espirro/efeitos dos fármacos
[Pt] Tipo de publicação:ENGLISH ABSTRACT; JOURNAL ARTICLE; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL
[Nm] Nome de substância:
0 (Piperidines); 01704YP3MO (Aminopyrine); 33361OE3AV (diphenylpyraline); 362O9ITL9D (Acetaminophen); 695DKH33EI (Nylidrin)
[Em] Mês de entrada:1204
[Cu] Atualização por classe:131121
[Lr] Data última revisão:
131121
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:120228
[St] Status:MEDLINE


  2 / 122 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:12950886
[Au] Autor:Bartlett H; Eperjesi F
[Ad] Endereço:Neurosciences Research Institute, School of Life and Health Sciences, Aston University, Aston Triangle, Birmingham B4 7ET, UK. bartlehe@aston.ac.uk
[Ti] Título:Age-related macular degeneration and nutritional supplementation: a review of randomised controlled trials.
[So] Source:Ophthalmic Physiol Opt;23(5):383-99, 2003 Sep.
[Is] ISSN:0275-5408
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:Age-related macular degeneration (AMD) is the leading cause of severe vision loss in the developed world. The lack of effective treatment modalities, coupled with evidence supporting an oxidative pathogenesis, has increased interest in the potential preventative role of nutritional supplementation. This article reviews seven randomised controlled trials (RCTs) that have investigated the role of nutritional supplementation in AMD. Three of these trials reported a positive effect of nutritional supplementation on AMD; the Age-related eye study (AREDS), the Lutein Antioxidant Supplementation Trial (LAST), and the oral zinc trial by Newsome et al. (1988). However, the oral zinc trial by Newsome et al. (1988) was unlikely to detect any difference between treatments smaller than 72%, and the AREDS results were based on a subgroup of their study population. Lutein was considered for the AREDS formulation, but was not commercially available at that time. The findings of the LAST support a possible therapeutic role of lutein in AMD.
[Mh] Termos MeSH primário: Suplementos Nutricionais
Degeneração Macular/dietoterapia
Vitamina E/análogos & derivados
[Mh] Termos MeSH secundário: Antioxidantes/administração & dosagem
Ácido Ascórbico/administração & dosagem
Carotenoides/metabolismo
Combinação de Medicamentos
Seres Humanos
Luteína/administração & dosagem
Degeneração Macular/etiologia
Nilidrina/administração & dosagem
Ensaios Clínicos Controlados Aleatórios como Assunto
Vitamina E/administração & dosagem
Vitaminas/metabolismo
Zinco/administração & dosagem
alfa-Tocoferol/administração & dosagem
beta Caroteno/administração & dosagem
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T; REVIEW
[Nm] Nome de substância:
0 (Antioxidants); 0 (Drug Combinations); 0 (Vitamins); 0 (alpha tocopherol, ascorbic acid, betacarotene, buphenine hydrochloride drug combination); 01YAE03M7J (beta Carotene); 1406-18-4 (Vitamin E); 36-88-4 (Carotenoids); 695DKH33EI (Nylidrin); H4N855PNZ1 (alpha-Tocopherol); J41CSQ7QDS (Zinc); PQ6CK8PD0R (Ascorbic Acid); X72A60C9MT (Lutein)
[Em] Mês de entrada:0311
[Cu] Atualização por classe:131121
[Lr] Data última revisão:
131121
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:030903
[St] Status:MEDLINE


  3 / 122 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:9719603
[Au] Autor:Tamiz AP; Whittemore ER; Zhou ZL; Huang JC; Drewe JA; Chen JC; Cai SX; Weber E; Woodward RM; Keana JF
[Ad] Endereço:Department of Chemistry, University of Oregon, Eugene, Oregon 97403, USA.
[Ti] Título:Structure-activity relationships for a series of bis(phenylalkyl)amines: potent subtype-selective inhibitors of N-methyl-D-aspartate receptors.
[So] Source:J Med Chem;41(18):3499-506, 1998 Aug 27.
[Is] ISSN:0022-2623
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:A series of bis(phenylalkyl)amines, structural analogues of ifenprodil and nylidrin, were synthesized and tested for antagonism of N-methyl-D-aspartate (NMDA) receptors. Potency and subunit selectivity were assayed by electrical recordings in Xenopus oocytes expressing three binary combinations of cloned rat NMDA receptor subunits: NR1A expressed in combination with either NR2A, NR2B, or NR2C. The bis(phenylalkyl)amines were selective antagonists of NR1A/2B receptors. Assayed under steady-state conditions, the most potent of these, N-[2-(4-hydroxyphenyl)ethyl]-5-phenylpentylamine hydrochloride (20), has an IC50 value of 8 nM and >1000-fold selectivity with respect to NR1A/2A and NR1A/2C receptors. The structure-activity relationship of the bis(phenylalkyl)amine series indicates that the piperidine ring and alkyl chain substitutions common to NR2B-selective antagonists such as ifenprodil, CP 101,606, and Ro 25-6981 are not necessary to generate potent and selective ligands. The primary determinants of potency are the phenolic OH group, acting as a hydrogen bond donor, the distance between the two rings, and an electrostatic interaction between the receptor and the basic nitrogen atom. This study provides a framework for designing structurally novel NR2B-selective antagonists which may be useful for treatment of a variety of neurological disorders.
[Mh] Termos MeSH primário: Butilaminas
Antagonistas de Aminoácidos Excitatórios
Fenóis
Receptores de N-Metil-D-Aspartato/antagonistas & inibidores
[Mh] Termos MeSH secundário: Animais
Butilaminas/síntese química
Butilaminas/química
Butilaminas/farmacologia
Antagonistas de Aminoácidos Excitatórios/síntese química
Antagonistas de Aminoácidos Excitatórios/química
Antagonistas de Aminoácidos Excitatórios/farmacologia
Nilidrina/farmacologia
Oócitos
Fenóis/síntese química
Fenóis/química
Fenóis/farmacologia
Ratos
Receptores de N-Metil-D-Aspartato/biossíntese
Proteínas Recombinantes/antagonistas & inibidores
Proteínas Recombinantes/biossíntese
Relação Estrutura-Atividade
Xenopus laevis
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Butylamines); 0 (Excitatory Amino Acid Antagonists); 0 (N-(2-(4-hydroxyphenyl)ethyl)-5-phenylpentylamine); 0 (Phenols); 0 (Receptors, N-Methyl-D-Aspartate); 0 (Recombinant Proteins); 695DKH33EI (Nylidrin)
[Em] Mês de entrada:9809
[Cu] Atualização por classe:131121
[Lr] Data última revisão:
131121
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:980828
[St] Status:MEDLINE


  4 / 122 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:9430414
[Au] Autor:Whittemore ER; Ilyin VI; Konkoy CS; Woodward RM
[Ad] Endereço:CoCensys Inc., Irvine, CA 92618, USA.
[Ti] Título:Subtype-selective antagonism of NMDA receptors by nylidrin.
[So] Source:Eur J Pharmacol;337(2-3):197-208, 1997 Oct 22.
[Is] ISSN:0014-2999
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:The 1,4-di-substituted piperidines ifenprodil, eliprodil, CP 101,606 ((1S,2S)-1-(4-hydroxyphenyl)-2-(4-hydroxy-4-phenylpiperidino)-1-propanol ) and Ro 25-6981 ((R-(R*,S*))-alpha-(4-hydroxyphenyl)-beta-methyl-4-(phenyl-methyl)-1- piperidinepropanol) are allosteric antagonists of NMDA receptors. Inhibition of diheteromeric NMDA receptors by this class of antagonist is characterized by pronounced selectivity for NR1/2B subunit combinations. In the current study, we assayed effects of nylidrin, a structurally-related non-piperidine, on recombinant and neuronal NMDA receptors. Nylidrin was a potent (IC50 = 0.18 microM) antagonist of NR1A/2B receptors expressed in Xenopus oocytes and was at least 150-fold weaker against NR1A/2A and NR1A/2C receptors. The blockade of NR1A/2B responses by nylidrin was not surmounted by increasing the concentrations of glutamate or glycine and was not voltage-dependent. Potency of inhibition increased approximately 3-fold upon lowering extracellular pH from 8 to 6.8. Nylidrin inhibited NMDA responses in cultured rat cortical neurons with similar potency and apparent mechanism of action as the NR1A/2B receptors. Our results suggest that nylidrin interacts with the same allosteric inhibitory site previously described for the related piperidine antagonists, and should serve as a structural lead for designing novel subtype-selective inhibitors of NMDA receptors.
[Mh] Termos MeSH primário: Antagonistas de Aminoácidos Excitatórios/farmacologia
Nilidrina/farmacologia
Receptores de N-Metil-D-Aspartato/antagonistas & inibidores
[Mh] Termos MeSH secundário: Animais
Células Cultivadas
Córtex Cerebral/citologia
Córtex Cerebral/efeitos dos fármacos
Córtex Cerebral/metabolismo
Sinergismo Farmacológico
Agonistas de Aminoácidos Excitatórios/farmacologia
Concentração de Íons de Hidrogênio
Potenciais da Membrana/fisiologia
Neurônios/efeitos dos fármacos
Neurônios/metabolismo
Oócitos
Ratos
Ratos Sprague-Dawley
Receptores de N-Metil-D-Aspartato/genética
Proteínas Recombinantes/antagonistas & inibidores
Proteínas Recombinantes/genética
Xenopus
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Excitatory Amino Acid Agonists); 0 (Excitatory Amino Acid Antagonists); 0 (Receptors, N-Methyl-D-Aspartate); 0 (Recombinant Proteins); 695DKH33EI (Nylidrin)
[Em] Mês de entrada:9803
[Cu] Atualização por classe:131121
[Lr] Data última revisão:
131121
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:980116
[St] Status:MEDLINE


  5 / 122 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:9143010
[Au] Autor:Pahk AJ; Williams K
[Ad] Endereço:Department of Pharmacology, University of Pennsylvania, School of Medicine, Philadelphia 19104-6084, USA.
[Ti] Título:Influence of extracellular pH on inhibition by ifenprodil at N-methyl-D-aspartate receptors in Xenopus oocytes.
[So] Source:Neurosci Lett;225(1):29-32, 1997 Mar 28.
[Is] ISSN:0304-3940
[Cp] País de publicação:Ireland
[La] Idioma:eng
[Ab] Resumo:Ifenprodil is an atypical N-methyl-D-aspartate (NMDA) receptor antagonist that selectively blocks receptors containing the NR2B subunit. It has been proposed that ifenprodil may act at a stimulatory polyamine site on NMDA receptors, although interactions between ifenprodil and polyamines are non-competitive. NMDA receptors are also inhibited by extracellular protons, and an interaction between protons and polyamine stimulation has been described. Using voltage-clamp recording of recombinant NR1/NR2B receptors expressed in oocytes, ifenprodil inhibition was found to be pH sensitive with a smaller inhibition at alkaline pH. Similar effects of pH were seen on inhibition by nylidrin, eliprodil, and haloperidol, which are thought to act at the ifenprodil binding site. The pH sensitivity of ifenprodil block occurs at NR1B/NR2B as well as NR1A/NR2B receptors, suggesting that it is not influenced by the exon-5 insert that is present in NR1B but absent in NR1A. Protons may directly affect the ifenprodil binding site or may alter the coupling of ifenprodil binding to inhibition of channel gating.
[Mh] Termos MeSH primário: Antagonistas de Aminoácidos Excitatórios/farmacologia
Fármacos Neuroprotetores/farmacologia
Oócitos/efeitos dos fármacos
Piperidinas/farmacologia
Receptores de N-Metil-D-Aspartato/antagonistas & inibidores
[Mh] Termos MeSH secundário: Animais
Haloperidol/farmacologia
Concentração de Íons de Hidrogênio
Nilidrina/farmacologia
Técnicas de Patch-Clamp
Xenopus laevis
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, U.S. GOV'T, P.H.S.
[Nm] Nome de substância:
0 (Excitatory Amino Acid Antagonists); 0 (Neuroprotective Agents); 0 (Piperidines); 0 (Receptors, N-Methyl-D-Aspartate); 695DKH33EI (Nylidrin); J6292F8L3D (Haloperidol); R8OE3P6O5S (ifenprodil); YW62A6TW29 (eliprodil)
[Em] Mês de entrada:9707
[Cu] Atualização por classe:131121
[Lr] Data última revisão:
131121
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:970328
[St] Status:MEDLINE


  6 / 122 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:8892364
[Au] Autor:Salokorpi T; Eronen M; von Wendt L
[Ad] Endereço:Department of Paediatric Neurology, University of Helsinki, Finland.
[Ti] Título:Growth and development until 18 months of children exposed to tocolytics indomethacin or nylidrin.
[So] Source:Neuropediatrics;27(4):174-7, 1996 Aug.
[Is] ISSN:0174-304X
[Cp] País de publicação:Germany
[La] Idioma:eng
[Ab] Resumo:Indomethacin, a prostaglandin synthesis inhibitor, is a more efficient tocolytic than the beta-sympathomimetic nylidrin, but causes more frequent unwanted effects in the neonatal period. In order to elucidate the effects on neurodevelopment, infants randomly exposed in utero to either compound were followed up to 18 months. A total of 93 children (40 exposed to nylidrin and 53 exposed to indomethacin) were examined at the age of 12 months. A detailed neurological examination was carried out in 44 of these infants at the age of 18 months. At the age of 12 months the children in the indomethacin group showed poor outcome (death or severe BPD and/or CP and/or severe ROP) in 23% and the children in the nylidrin group in 5% (p = 0.039, Fisher Exact Test). Concerning the children born during tocolysis the corresponding figures were 73% and 13% respectively (p = 0.002, Fisher Exact Test). The growth of the children did not differ significantly between the two treatment groups. Neurological assessment at the age of 18 months revealed more subnormally scoring children in the indomethacin group, but the differences were not significant. It was concluded that the higher incidence of poor outcome and a lest favourable neurological development in the indomethacin group do not support indomethacin's position as the drug of choice for tocolysis.
[Mh] Termos MeSH primário: Desenvolvimento Infantil/efeitos dos fármacos
Crescimento/efeitos dos fármacos
Indometacina/efeitos adversos
Nilidrina/efeitos adversos
Efeitos Tardios da Exposição Pré-Natal
Tocolíticos/efeitos adversos
[Mh] Termos MeSH secundário: Feminino
Seguimentos
Seres Humanos
Recém-Nascido
Recém-Nascido Prematuro/crescimento & desenvolvimento
Recém-Nascido Prematuro/fisiologia
Gravidez
Distribuição por Sexo
Resultado do Tratamento
Trigêmeos
Gêmeos
[Pt] Tipo de publicação:CLINICAL TRIAL; JOURNAL ARTICLE; RANDOMIZED CONTROLLED TRIAL
[Nm] Nome de substância:
0 (Tocolytic Agents); 695DKH33EI (Nylidrin); XXE1CET956 (Indomethacin)
[Em] Mês de entrada:9702
[Cu] Atualização por classe:131121
[Lr] Data última revisão:
131121
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:960801
[St] Status:MEDLINE


  7 / 122 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:8751336
[Au] Autor:Kaiser HJ; Flammer J; Stümpfig D; Hendrickson P
[Ad] Endereço:University Eye Clinic, Basle, Switzerland.
[Ti] Título:Visaline in the treatment of age-related macular degeneration: a pilot study.
[So] Source:Ophthalmologica;209(6):302-5, 1995.
[Is] ISSN:0030-3755
[Cp] País de publicação:Switzerland
[La] Idioma:eng
[Ab] Resumo:Age-related macular degeneration (AMD) is the main cause of a reduction in visual acuity in patients over the age of 65 years. A positive influence of medical treatment (i.e. with vitamins and trace minerals) has been suggested but remains unproven. In this randomized, double-blind study, 20 patients in an early stage of AMD were included. Over a period of 6 months, 9 patients were treated with Visaline and 11 with a placebo. The effect of the treatment was not statistically different between the two groups, admittedly small in number, in terms of visual and retinal acuity, color vision, and contrast sensitivity. Despite the lack of such measureable differences, the patients' own subjective assessments, however, were much better in the Visaline-treated group. Due to the short duration of the observation time, we can not comment on a possible long-term effect.
[Mh] Termos MeSH primário: Agonistas Adrenérgicos beta/uso terapêutico
Antioxidantes/uso terapêutico
Degeneração Macular/tratamento farmacológico
alfa-Tocoferol/análogos & derivados
[Mh] Termos MeSH secundário: Idoso
Ácido Ascórbico/uso terapêutico
Método Duplo-Cego
Combinação de Medicamentos
Feminino
Seres Humanos
Pressão Intraocular
Degeneração Macular/fisiopatologia
Masculino
Nilidrina/uso terapêutico
Projetos Piloto
Comprimidos
Tocoferóis
Visão Ocular/fisiologia
Acuidade Visual
Vitamina E/análogos & derivados
Vitamina E/uso terapêutico
beta Caroteno/uso terapêutico
[Pt] Tipo de publicação:CLINICAL TRIAL; COMPARATIVE STUDY; JOURNAL ARTICLE; RANDOMIZED CONTROLLED TRIAL
[Nm] Nome de substância:
0 (Adrenergic beta-Agonists); 0 (Antioxidants); 0 (Drug Combinations); 0 (Tablets); 0 (alpha tocopherol, ascorbic acid, betacarotene, buphenine hydrochloride drug combination); 01YAE03M7J (beta Carotene); 1406-18-4 (Vitamin E); 695DKH33EI (Nylidrin); H4N855PNZ1 (alpha-Tocopherol); PQ6CK8PD0R (Ascorbic Acid); R0ZB2556P8 (Tocopherols)
[Em] Mês de entrada:9612
[Cu] Atualização por classe:171116
[Lr] Data última revisão:
171116
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:950101
[St] Status:MEDLINE


  8 / 122 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:8176569
[Au] Autor:Eronen M; Pesonen E; Kurki T; Teramo K; Ylikorkala O; Hallman M
[Ad] Endereço:Children's Hospital, University of Helsinki, Finland.
[Ti] Título:Increased incidence of bronchopulmonary dysplasia after antenatal administration of indomethacin to prevent preterm labor.
[So] Source:J Pediatr;124(5 Pt 1):782-8, 1994 May.
[Is] ISSN:0022-3476
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:The aim of this randomized study was to compare the neonatal outcome in infants who have been exposed in utero to indomethacin with that in infants exposed to a beta-adrenergic agonist, nylidrin hydrochloride. Eighty pregnant women threatened with preterm labor between 24 and 34 weeks of gestation were enrolled in the study. An intravenous infusion of nylidrin or enterally administered indomethacin was given for a maximum of 72 hours. If preterm labor recurred, all parturient patients were treated with nylidrin. Indomethacin prolonged gestation significantly more than the beta-adrenergic agonist (6.6 weeks vs 4.5 weeks; p = 0.04). Ten of the forty-two infants exposed to indomethacin and 2 of the 45 infants exposed to nylidrin had bronchopulmonary dysplasia (24% vs 5%; p = 0.02). Among the 28 infants delivered within 120 hours after the start of treatment, the incidences of respiratory distress syndrome (82% vs 29%; p = 0.02), bronchopulmonary dysplasia (73% vs 6%; p = 0.0006), and necrotizing enterocolitis or focal intestinal perforation (27% vs 0%; p = 0.03) were higher among those exposed to indomethacin than among those exposed to nylidrin. We infer that administration of indomethacin to pregnant women threatened with premature labor is associated with an increased risk of bronchopulmonary dysplasia in their infants if delivery occurs early.
[Mh] Termos MeSH primário: Displasia Broncopulmonar/induzido quimicamente
Indometacina/uso terapêutico
Nilidrina/uso terapêutico
Trabalho de Parto Prematuro/prevenção & controle
Efeitos Tardios da Exposição Pré-Natal
Tocolíticos/efeitos adversos
[Mh] Termos MeSH secundário: Adulto
Feminino
Seres Humanos
Indometacina/efeitos adversos
Recém-Nascido
Recém-Nascido Prematuro
Gravidez
Tocólise/métodos
[Pt] Tipo de publicação:CLINICAL TRIAL; COMPARATIVE STUDY; JOURNAL ARTICLE; RANDOMIZED CONTROLLED TRIAL; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Tocolytic Agents); 695DKH33EI (Nylidrin); XXE1CET956 (Indomethacin)
[Em] Mês de entrada:9406
[Cu] Atualização por classe:131121
[Lr] Data última revisão:
131121
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:940501
[St] Status:MEDLINE


  9 / 122 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:8378121
[Au] Autor:Eronen M
[Ad] Endereço:Children's Hospital, Division of Pediatric Cardiology, University of Helsinki, Finland.
[Ti] Título:The hemodynamic effects of antenatal indomethacin and a beta-sympathomimetic agent on the fetus and the newborn: a randomized study.
[So] Source:Pediatr Res;33(6):615-9, 1993 Jun.
[Is] ISSN:0031-3998
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:To study the effect of antenatal indomethacin or nylidrin hydrochloride treatment on the fetal and neonatal ductus arteriosus and tricuspid valve function, 84 pregnant women with threatened premature birth between 22.9 and 34.0 wk gestation and 94 of their offspring born at 24.7 to 41.6 wk of gestation were studied by Doppler echocardiography. Forty-six women were treated with indomethacin and 38 with nylidrin. Both peak systolic and peak diastolic velocities in the ductus increased after administration of indomethacin and exceeded the corresponding velocities in the fetuses of the nylidrin group (p = 0.0001). Ductal constriction occurred in 42 of 49 fetuses treated with indomethacin (86%). Tricuspid valve regurgitation (TR) was evident in 11 of 49 fetuses treated with indomethacin (22%). The mean gestational age of the fetuses with TR (30.0 wk) tended to be higher than those without TR (28.3 wk, p = 0.056). In the nylidrin group, no fetus had ductal constriction or TR. A significant increase in peak systolic velocity (r = 0.54, p = 0.0001) and in peak diastolic velocity (r = 0.46, p = 0.0001) in the ductus with advancing gestational age was demonstrated in the indomethacin group; however, in the nylidrin group, there was a less remarkable increase in peak systolic velocity (r = 0.35, p = 0.04) and no increase in peak diastolic velocity (r = 0.02, p = 0.93). In infants born at or before 35 wk gestation, incidences of both spontaneous closure and indomethacin-induced closure of ductus were similar in both study groups (p > 0.1).(ABSTRACT TRUNCATED AT 250 WORDS)
[Mh] Termos MeSH primário: Permeabilidade do Canal Arterial/tratamento farmacológico
Feto/efeitos dos fármacos
Hemodinâmica/efeitos dos fármacos
Indometacina/farmacologia
Nilidrina/farmacologia
[Mh] Termos MeSH secundário: Adulto
Velocidade do Fluxo Sanguíneo/efeitos dos fármacos
Permeabilidade do Canal Arterial/fisiopatologia
Permeabilidade do Canal Arterial/prevenção & controle
Feminino
Doenças Fetais/tratamento farmacológico
Feto/fisiologia
Idade Gestacional
Seres Humanos
Indometacina/administração & dosagem
Recém-Nascido
Masculino
Troca Materno-Fetal
Nilidrina/administração & dosagem
Gravidez
[Pt] Tipo de publicação:CLINICAL TRIAL; COMPARATIVE STUDY; JOURNAL ARTICLE; RANDOMIZED CONTROLLED TRIAL; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
695DKH33EI (Nylidrin); XXE1CET956 (Indomethacin)
[Em] Mês de entrada:9310
[Cu] Atualização por classe:131121
[Lr] Data última revisão:
131121
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:930601
[St] Status:MEDLINE


  10 / 122 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
[PMID]:1733190
[Au] Autor:Kurki T; Viinikka L; Ylikorkala O
[Ad] Endereço:I Department of Obstetrics and Gynecology, University of Central Hospital of Helsinki, Finland.
[Ti] Título:Urinary excretion of prostacyclin and thromboxane metabolites in threatened preterm labor: effect of indomethacin and nylidrin.
[So] Source:Am J Obstet Gynecol;166(1 Pt 1):150-4, 1992 Jan.
[Is] ISSN:0002-9378
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:OBJECTIVE: We studied the role of smooth muscle-relaxing prostacyclin and its endogenous antagonist, thromboxane A2, in preterm labor by assessing the urinary output of the breakdown products of prostacyclin (6-keto-prostaglandin F1 alpha and 2,3-dinor-6-keto-prostaglandin F1 alpha) and those of thromboxane A2 (thromboxane B2, 2,3-dinor-thromboxane B2). STUDY DESIGN: Thirty-three women in preterm labor between 25 and 34 weeks of gestation were studied before, during, and after treatment with indomethacin (n = 16) or nylidrin (n = 17). Urinary prostanoid levels were determined by high-performance liquid chromatography followed by radioimmunoassay, and the excretion was expressed as nanograms of prostanoids per millimole of creatinine. Statistical analyses were done by paired and unpaired Student t test, by Spearman's correlation, and by Wilcoxon signed-rank test. RESULTS: Preterm labor was accompanied by a median 32% higher output of prostacyclin and thromboxane A2 metabolites as compared with those in 25 controls. At 8 hours after the start of treatment indomethacin induced maximal drops in 6-keto-prostaglandin F1 alpha (70%), in dinor-6-keto-prostaglandin F1 alpha (60%), in thromboxane B2 (85%), and in dinor-thromboxane B2 (95%) excretion. Within 1 week after the cessation of indomethacin, output of prostacyclin metabolites had recovered to pretreatment values, whereas output of thromboxane A2 metabolites was yet lower than the pretreatment value. Nylidrin induced no change in the output of prostacyclin and thromboxane A2 metabolites. CONCLUSION: Threatened preterm labor is associated with a rise in prostacyclin and thromboxane A2 synthesis. Indomethacin inhibits more thromboxane A2 than does prostacyclin synthesis. These findings may explain the fetal vascular changes during maternal indomethacin treatment.
[Mh] Termos MeSH primário: Epoprostenol/urina
Indometacina/uso terapêutico
Nilidrina/uso terapêutico
Trabalho de Parto Prematuro/urina
Tromboxano B2/urina
[Mh] Termos MeSH secundário: 6-Cetoprostaglandina F1 alfa/análogos & derivados
6-Cetoprostaglandina F1 alfa/urina
Adulto
Feminino
Seres Humanos
Cinética
Trabalho de Parto Prematuro/tratamento farmacológico
Gravidez
Tromboxano B2/análogos & derivados
Tocólise
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
54397-85-2 (Thromboxane B2); 58962-34-8 (6-Ketoprostaglandin F1 alpha); 63250-09-9 (2,3-dinor-thromboxane B2); 64700-71-6 (2,3-dinor-6-ketoprostaglandin F1alpha); 695DKH33EI (Nylidrin); DCR9Z582X0 (Epoprostenol); XXE1CET956 (Indomethacin)
[Em] Mês de entrada:9202
[Cu] Atualização por classe:170908
[Lr] Data última revisão:
170908
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:920101
[St] Status:MEDLINE



página 1 de 13 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde